WO2001005963A3 - ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1) - Google Patents

ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1) Download PDF

Info

Publication number
WO2001005963A3
WO2001005963A3 PCT/CA2000/000824 CA0000824W WO0105963A3 WO 2001005963 A3 WO2001005963 A3 WO 2001005963A3 CA 0000824 W CA0000824 W CA 0000824W WO 0105963 A3 WO0105963 A3 WO 0105963A3
Authority
WO
WIPO (PCT)
Prior art keywords
mglur1
antisense oligonucleotides
receptor type
glutamate receptor
metabotropic glutamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2000/000824
Other languages
French (fr)
Other versions
WO2001005963A2 (en
Inventor
Marian E Fundytus
Terence J Coderre
S Robin Cohen
James L Henry
Anneli Vainio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to AU59599/00A priority Critical patent/AU5959900A/en
Priority to CA002377937A priority patent/CA2377937A1/en
Priority to EP00945507A priority patent/EP1238069A2/en
Publication of WO2001005963A2 publication Critical patent/WO2001005963A2/en
Publication of WO2001005963A3 publication Critical patent/WO2001005963A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to antisense oligonucleotides for metabotropic glutamate receptor type 1 (mGluR1). There is provided oligonucleotides that hybridize to a mRNA encoding mGluR1 or a splice variant thereof. There is also provided a method for treating a patient having a disorder related to an elevated glutamate level, such as chronic pain, or to enhance an opioid effect or to reduce opioid dependence and/or tolerance, which comprises the administration of such an oligonucleotide. Specific pain treatment is thereby obtained.
PCT/CA2000/000824 1999-07-15 2000-07-17 ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1) Ceased WO2001005963A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU59599/00A AU5959900A (en) 1999-07-15 2000-07-17 Oligonucleotides for metabotropic glutamate receptor type 1 (mglur1)
CA002377937A CA2377937A1 (en) 1999-07-15 2000-07-17 Oligoneucleotides for metabotropic glutamate receptor type 1 (mglur1)
EP00945507A EP1238069A2 (en) 1999-07-15 2000-07-17 Antisense oligonucleotides for metabotropic glutamate receptor type 1 (mglur1)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14400499P 1999-07-15 1999-07-15
US60/144,004 1999-07-15

Publications (2)

Publication Number Publication Date
WO2001005963A2 WO2001005963A2 (en) 2001-01-25
WO2001005963A3 true WO2001005963A3 (en) 2001-11-08

Family

ID=22506645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000824 Ceased WO2001005963A2 (en) 1999-07-15 2000-07-17 ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1)

Country Status (4)

Country Link
EP (1) EP1238069A2 (en)
AU (1) AU5959900A (en)
CA (1) CA2377937A1 (en)
WO (1) WO2001005963A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357808T3 (en) * 2001-06-07 2011-04-29 Christine Dr. Sang TREATMENT OF NEUROPATHIC PAIN WITH ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTOR (NMDA).
WO2005075987A2 (en) * 2004-01-28 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 1 (mglur1)
JP2008504840A (en) 2004-06-30 2008-02-21 アルニラム ファーマスーティカルズ インコーポレイテッド Oligonucleotides containing non-phosphate backbone bonds
PL2083811T3 (en) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Methods of treating down's syndrome, fragile x syndrome and autism
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
CN120310791A (en) 2018-01-12 2025-07-15 百时美施贵宝公司 Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US12241065B2 (en) 2018-01-12 2025-03-04 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; FUNDYTUS, M. E. (1) ET AL: "An antisense oligonucleotide targeting mGluR1 attenuates allodynia/hyperalgesia in a model of chronic inflammation in rats.", XP002153939, retrieved from STN *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; FUNDYTUS, M. E. (1) ET AL: "Antisense oligonucleotides targeting group I mGluRs attenuate nerve constriction-induced hyperalgesia and allodynia.", XP002153940, retrieved from STN *
FAN, Z. (1) ET AL: "Inhibition of kindling by mGLUR1 antisense.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1998) VOL. 24, NO. 1-2, PP. 1936. MEETING INFO.: 28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 2 LOS ANGELES, CALIFORNIA, USA NOVEMBER 7-12, 1998 SOCIETY FOR NEUROSCIENCE., XP000943868 *
FUNDYTUS M E ET AL: "In vivo antinociceptive activity of anti-rat mGluR1 and mGluR5 antibodies in rats.", NEUROREPORT, (1998 MAR 9) 9 (4) 731-5., XP002128754 *
FUNDYTUS M.E.: "Common mechanisms underlying opioid tolerance and dependence, and neuropathic pain: Role of metabotropic glutamate receptors.", PAIN RESEARCH AND MANAGEMENT, (2000) 5/1 (40-48)., XP000995096 *
GANNON R L ET AL: "In situ hybridization of antisense mRNA oligonucleotides for AMPA, NMDA and metabotropic glutamate receptor subtypes in the rat suprachiasmatic nucleus at different phases of the circadian cycle.", BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1994 JUN) 23 (4) 338-44., XP000943864 *
MUKHIN A ET AL: "Activation of metabotropic glutamate receptor subtype mGluR1 contributes to post-traumatic neuronal injury.", JOURNAL OF NEUROSCIENCE, (1996 OCT 1) 16 (19) 6012-20., XP000943935 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1997) VOL. 23, NO. 1-2, PP. 1013. MEETING INFO.: 27TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 1 NEW ORLEANS, LOUISIANA, USA OCTOBER 25-30, 1997 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1998) VOL. 24, NO. 1-2, PP. 1870. MEETING INFO.: 28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 2 LOS ANGELES, CALIFORNIA, USA NOVEMBER 7-12, 1998 SOCIETY FOR NEUROSCIENCE. *
YOUNG M R ET AL: "Antisense ablation of type I metabotropic glutamate receptor mGluR1 inhibits spinal nociceptive transmission.", JOURNAL OF NEUROSCIENCE, (1998 DEC 1) 18 (23) 10180-8., XP000943934 *

Also Published As

Publication number Publication date
AU5959900A (en) 2001-02-05
WO2001005963A2 (en) 2001-01-25
CA2377937A1 (en) 2001-01-25
EP1238069A2 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
CA2458806A1 (en) Antisense oligonucleotide against human ache and uses thereof
WO2004014881A3 (en) '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
AP2003002761A0 (en) Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers
AU4743601A (en) Neutral antagonists and use thereof in treating drug abuse
WO1998011211A3 (en) Method for using oligonucleotides having modified cpg dinucleosides
DK0867184T3 (en) Use of tiagabine for the treatment of sleep disorders
EP1426375A3 (en) Analgesic spiroindole derivatives
WO2003096983A3 (en) Method of treating dyslipidemic disorders
WO2008066776A3 (en) Methods for treating hypercholesterolemia
TW200607509A (en) Use of optically pure (S,S) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
WO2001005391A3 (en) Method for treating chronic pain using mek inhibitors
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
ZA9711279B (en) Method for treating and preventing neurological disorders and promoting wound healing.
MY138394A (en) Combination of mglur2 antagonist and ache inhibitor
WO2001097794A8 (en) Inhibitors of matriptase for the treatment of cancer
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
WO2002060454A3 (en) Use of dinucleoside polyphosphate to stimulate removal of fluid in retinal disorders
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
WO2003015690A3 (en) Method for treating primary insomnia
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
WO2004028464A3 (en) Methods and compositions for modification of splicing of pre-mrna
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation
MA26592A1 (en) METHOD AND MEDICAMENT USING CYCLIC COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY
WO2006133286A3 (en) Treatment of tnf antagonist-resistant inflammatory disorders and related methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2377937

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000945507

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000945507

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000945507

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP